{
    "organizations": [],
    "uuid": "6700156332245bb4262970ae41a8c3683607aa6a",
    "author": "",
    "url": "https://www.reuters.com/article/brief-pfizer-reports-q1-earnings-of-059/brief-pfizer-reports-q1-earnings-of-0-59-per-share-idUSASC09YI4",
    "ord_in_thread": 0,
    "title": "BRIEF-Pfizer Reports Q1 Earnings Of $0.59 Per Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 1, 2018 / 11:16 AM / in 6 minutes BRIEF-Pfizer Reports Q1 Earnings Of $0.59 Per Share Reuters Staff\nMay 1 (Reuters) - Pfizer Inc:\n* PFIZER REPORTS FIRST-QUARTER 2018 RESULTS * Q1 EARNINGS PER SHARE $0.59\n* Q1 EARNINGS PER SHARE VIEW $0.74 — THOMSON REUTERS I/B/E/S * REAFFIRMED ALL COMPONENTS OF 2018 FINANCIAL GUIDANCE\n* QTRLY INNOVATIVE HEALTH SEGMENT REVENUE $7,829 MILLION VERSUS $7,415 MILLION * Q1 REVENUE VIEW $13.13 BILLION — THOMSON REUTERS I/B/E/S\n* 2018 FINANCIAL GUIDANCE FOR ADJUSTED DILUTED EPS NOW ANTICIPATES SHARE REPURCHASES TOTALING ABOUT $6.1 BILLION IN 2018\n* PFIZER - CONTINUES TO EXPECT THAT ANY DECISION REGARDING STRATEGIC ALTERNATIVES FOR CONSUMER HEALTHCARE WILL BE MADE DURING 2018\n* PFIZER - Q1 ESSENTIAL HEALTH BUSINESS NEGATIVELY IMPACTED BY CONTINUED LEGACY HOSPIRA PRODUCT SUPPLY SHORTAGES IN U.S., PRODUCT LOSSES OF EXCLUSIVITY\n* PFIZER-2018 GUIDANCE REFLECTS ANTICIPATED NEGATIVE REVENUE IMPACT OF $2.0 BILLION DUE TO RECENT, EXPECTED GENERIC, BIOSIMILAR COMPETITION FOR CERTAIN PRODUCTS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)",
    "published": "2018-05-01T14:14:00.000+03:00",
    "crawled": "2018-05-01T14:29:26.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "minute",
        "report",
        "q1",
        "earnings",
        "per",
        "share",
        "reuters",
        "staff",
        "may",
        "reuters",
        "pfizer",
        "inc",
        "pfizer",
        "report",
        "result",
        "q1",
        "earnings",
        "per",
        "share",
        "q1",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "reaffirmed",
        "component",
        "financial",
        "guidance",
        "qtrly",
        "innovative",
        "health",
        "segment",
        "revenue",
        "million",
        "versus",
        "million",
        "q1",
        "revenue",
        "view",
        "billion",
        "thomson",
        "reuters",
        "financial",
        "guidance",
        "adjusted",
        "diluted",
        "eps",
        "anticipates",
        "share",
        "repurchase",
        "totaling",
        "billion",
        "pfizer",
        "continues",
        "expect",
        "decision",
        "regarding",
        "strategic",
        "alternative",
        "consumer",
        "healthcare",
        "made",
        "pfizer",
        "q1",
        "essential",
        "health",
        "business",
        "negatively",
        "impacted",
        "continued",
        "legacy",
        "hospira",
        "product",
        "supply",
        "shortage",
        "product",
        "loss",
        "exclusivity",
        "guidance",
        "reflects",
        "anticipated",
        "negative",
        "revenue",
        "impact",
        "billion",
        "due",
        "recent",
        "expected",
        "generic",
        "biosimilar",
        "competition",
        "certain",
        "product",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}